Skip to main content
Clinical Trials/EUCTR2006-002337-20-NL
EUCTR2006-002337-20-NL
Active, not recruiting
Not Applicable

Efficacy of peripherally targeted inhaled rhDNase for persistent obstructive asthma in childhood

Erasmus Medical Centre Rotterdam0 sites60 target enrollmentJuly 5, 2006

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Asthma is a chronic inflammatory disorder in which many cells play a role, in particular mast cells, eosinophils and T lymphocytes. In susceptible individuals this inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness and cough. These symptoms are usually associated with widespread but variable airflow limitation that is at least partly reversible either spontaneously or with treatment.
Sponsor
Erasmus Medical Centre Rotterdam
Enrollment
60
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 5, 2006
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Erasmus Medical Centre Rotterdam

Eligibility Criteria

Inclusion Criteria

  • \- Age 6 – 18 years;
  • \- Asthma diagnosed according to GINA guidelines;
  • \- Attending the outpatient clinic for at least one year;
  • \- Treatment with at least 400 mg/day inhaled Budesonide or equivalent (dose constant for at least 6 months) and bronchodilators as needed or daily;
  • \- Clinically stable asthma while using a constant dose of ICS;
  • \- Ability to perform lung function tests (assessed by trained lung function technician);
  • \- Persistent peripheral airways obstruction as assessed by pulmonary function testing, defined as:
  • \* Dissociation between FVC and FEF75 values: FEF75 at least 20% (absolute % predicted) lower than FVC.
  • \- FVC within normal limits (for this study defined as FVC \> 80% pred).
  • Are the trial subjects under 18? yes

Exclusion Criteria

  • \- Asthma exacerbation with hospital admission in last 3 months;
  • \- Intensive Care Unit (ICU) admission for asthma in the last year;
  • \- Current respiratory tract infection;
  • \- Inability to follow instructions of the investigator;
  • \- Inability to inhale rhDNase;
  • \- Concomitant medical conditions that effect inhaled treatment (e.g. cleft palate, severe malacia);
  • \- Neuromuscular disease;
  • \- Smoking.

Outcomes

Primary Outcomes

Not specified

Similar Trials